3459-67-4

Basic information

• Product Name: m-aminobenzamidine hydrochloride
• Synonyms: m-aminobenzamidine hydrochloride;3-AMinobenziMidaMide HCl
• CAS NO: 3459-67-4
• Molecular Formula: C₇H₉N₃*2ClH
• Molecular Weight: 171.6274
• EINECS: 222-400-6
• Mol File: 3459-67-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 307.3°Cat760mmHg
• Flash Point: 139.7°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.00073mmHg at 25°C
• CAS DataBase Reference: m-aminobenzamidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: m-aminobenzamidine hydrochloride(3459-67-4)
• EPA Substance Registry System: m-aminobenzamidine hydrochloride(3459-67-4)

Safety Data

• Hazardous Substances Data: 3459-67-4(Hazardous Substances Data)

Usage

General Description

m-aminobenzamidine hydrochloride is a chemical compound used in biochemical and pharmaceutical research. It is a white to off-white crystalline powder that is soluble in water. This chemical is often used as a reagent for the determination of proteolytic activity and in the determination of trypsin and thrombin. It is also used in the preparation of substrates for monitoring enzyme activity and in the isolation and purification of nucleic acids. Overall, m-aminobenzamidine hydrochloride is an important tool in various scientific and medical applications.

InChI:InChI=1/C7H9N3.ClH/c8-6-3-1-2-5(4-6)7(9)10;/h1-4H,8H2,(H3,9,10);1H

Upstream product

• 56406-50-9 3-nitrobenzamidine hydrochloride 
• 3459-67-4 3-aminobenzamidine dihydrochloride 

Downstream Products

• 455900-78-4 3-[3-(4-benzylsulfamoyl-phenyl)-thioureido]-benzamidine 
• 1225062-24-7 3-(5-(3-aminophenyl)-4H-1,2,4-triazol-3-yl)-5-bromopyrazin-2-amine 
• 1350030-90-8 C₂₀H₂₄N₆O₂ 
• 1032471-11-6 C₂₀H₂₄N₆O₂ 

Relevant articles and documents

Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform

Hepsin is a membrane-anchored serine protease whose role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis. Using an integrated design, synthesis, and screening platform, we were able to rapidly develop potent and selective inhibitors of hepsin. In progressing from the initial hit 7 to compound 53, the IC50 value against hepsin was improved from ～1 μM to 22 nM, and the selectivity over urokinase-type plasminogen activator (uPA) was increased from 30-fold to >6000-fold. Subsequent in vitro ADMET profiling and cellular studies confirmed that the leading compounds are useful tools for interrogating the role of hepsin in breast tumorigenesis.